{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:05:04Z","timestamp":1790060704164,"version":"4.0.1"},"reference-count":38,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["KLSB2023KF\u201003"],"award-info":[{"award-number":["KLSB2023KF\u201003"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Both the GLP\u20101 receptor agonist semaglutide and the novel dual GIP\/GLP\u20101 receptor agonist tirzepatide have emerged as first\u2010line therapeutic options for metabolic diseases. However, their real\u2010world comparative safety profiles are difficult to interpret due to differential reporting composition in spontaneous reporting databases. This study compared their post\u2010marketing adverse event (AE) reporting patterns and examined how reporter identity influences signal prominence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>AE reports (May 2022\u2013June 2026) from FAERS were analysed using ROR, PRR, information component (IC) and empirical Bayes geometric mean (EBGM); a signal required simultaneous four\u2010method convergence; additionally, the Benjamini\u2013Hochberg false discovery rate (FDR) procedure was used to ensure signal robustness against multiple testing. Head\u2010to\u2010head comparisons used the ratio of reporting odds ratios (RORR) with 95% CIs, run in parallel across general population and healthcare professional (HCP)\u2010restricted subset, with sensitivity analyses by indication, seriousness, geography and calendar quarter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 151\u2009654 tirzepatide and 64\u2009987 semaglutide reports were analysed (HCP: 5.04% vs. 23.42%). Only semaglutide met four\u2010method criteria for gastrointestinal (ROR 3.64) and metabolic (ROR 4.25) disorders in the general population (GI RORR 0.58, 95% CI 0.57\u20130.59). Pancreatitis signalled for both agents but attenuated to equivalence within T2DM (RORR 0.98, 95% CI 0.83\u20131.15). Diabetic ketoacidosis signalled exclusively for semaglutide in the HCP cohort (ROR 3.52); tirzepatide showed higher hypoglycaemia reporting (RORR 1.91, 95% CI 1.49\u20132.44). In the HCP cohort, tirzepatide GI ROR rose to 2.53 and semaglutide acquired eye disorder reporting signals (ROR 2.61). All sensitivity analyses (stratified by indication, seriousness, geography restriction and calendar quarter) confirmed directional stability of these comparative reporting patterns across subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This FAERS\u2010based analysis identifies distinct AE reporting patterns between tirzepatide and semaglutide that are sensitive to reporter type; all findings are hypothesis\u2010generating and require confirmation with defined exposure denominators.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71373","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:26:41Z","timestamp":1790058401000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Adverse Event Reporting Patterns of Tirzepatide Versus Semaglutide: A Stratified Study of General and Healthcare Professional Cohorts in\n                    <scp>FAERS<\/scp>"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7626-7826","authenticated-orcid":false,"given":"XingYu","family":"Liu","sequence":"first","affiliation":[{"name":"Civil Aviation Shanghai Hospital Gubei Branch of Ruijin Hospital  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenFang","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Life Sciences Shanghai Normal University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"1","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12933-018-0731-y","article-title":"Clinical Application of Glucagon\u2010Like Peptide\u20101 Receptor Agonists in Cardiovascular Disease: Lessons From Recent Clinical Cardiovascular Outcomes Trials","volume":"17","author":"Tanaka A.","year":"2018","journal-title":"Cardiovascular Diabetology"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01646-9"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505928"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02441-z"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.23385"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2025.09.007"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.71088"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43856\u2010026\u201001750\u2010z"},{"issue":"7","key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/ijms27072988","article-title":"Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class\u2010Level Post\u2010Marketing Reporting Patterns in EudraVigilance","volume":"27","author":"Marin R. C.","year":"2026","journal-title":"International Journal of Molecular Sciences"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1323867"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14217678"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13182259"},{"issue":"2","key":"e_1_2_10_18_1","first-page":"e104376","article-title":"A Rare Case of Semaglutide\u2010Associated Small Bowel Obstruction Complicated by Acute Kidney Injury Requiring Dialysis","volume":"18","author":"Rallabandi S.","year":"2026","journal-title":"Cureus"},{"issue":"1","key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13195-025-01735-5","article-title":"Response to Xing et\u00a0al.: Post\u2010Marketing Safety Concerns With Lecanemab: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System Database","volume":"17","author":"Irizarry M.","year":"2025","journal-title":"Alzheimer's Research & Therapy"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2021.1954906"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04403-5"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-018-0134-0"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0150-2"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157753"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"issue":"3","key":"e_1_2_10_29_1","first-page":"247","article-title":"Case\u2010Non Case Studies: Principles, Methods, Bias and Interpretation","volume":"73","author":"Faillie J. L.","year":"2018","journal-title":"Th\u00e9rapie"},{"issue":"1","key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13058-025-02013-w","article-title":"Pharmacovigilance Study of Adverse Reactions of Anti\u2010HER\u20102 Drugs for the Treatment of HER\u20102\u2010Positive Breast Cancer Based on the FAERS Database","volume":"27","author":"Han J.","year":"2025","journal-title":"Breast Cancer Research"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/1906797"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14551"},{"issue":"5","key":"e_1_2_10_35_1","first-page":"e108868","article-title":"Ketoacidosis Risk in Non\u2010Diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System","volume":"18","author":"Makhmutov A.","year":"2026","journal-title":"Cureus"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S559919"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/biology9120473"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu18111688"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2393"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71373","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71373","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:26:42Z","timestamp":1790058402000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":38,"alternative-id":["10.1111\/dom.71373"],"URL":"https:\/\/doi.org\/10.1111\/dom.71373","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"2026-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"dom.71373"}}